RESUMO
BACKGROUND: In this study we aimed to evaluate the role of a SNP in intron 1 of the ERCC4 gene (rs744154), previously reported to be associated with a reduced risk of breast cancer in the general population, as a breast cancer risk modifier in BRCA1 and BRCA2 mutation carriers. METHODS: We have genotyped rs744154 in 9408 BRCA1 and 5632 BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and assessed its association with breast cancer risk using a retrospective weighted cohort approach. RESULTS: We found no evidence of association with breast cancer risk for BRCA1 (per-allele HR: 0.98, 95% CI: 0.93-1.04, P = 0.5) or BRCA2 (per-allele HR: 0.97, 95% CI: 0.89-1.06, P = 0.5) mutation carriers. CONCLUSION: This SNP is not a significant modifier of breast cancer risk for mutation carriers, though weak associations cannot be ruled out.
Assuntos
Proteínas de Ligação a DNA/genética , Genes BRCA1 , Genes BRCA2 , Heterozigoto , Mutação , Polimorfismo de Nucleotídeo Único , Estudos de Coortes , Feminino , Humanos , Estudos RetrospectivosAssuntos
Diabetes Mellitus/epidemiologia , Doenças Vasculares/epidemiologia , Adulto , Pressão Sanguínea , Colesterol/sangue , Feminino , Humanos , Hipercolesterolemia/epidemiologia , Hipertrigliceridemia/epidemiologia , Masculino , Pessoa de Meia-Idade , Prevalência , Fatores de Risco , Fumar/epidemiologia , Sri Lanka/epidemiologia , População Suburbana , Triglicerídeos/sangueRESUMO
The synthesis of enantiomerically enriched (+)-(R)-2-methyl-1-tetralone 1 (up to 29% e.e.) was achieved by enantioselective protonation of the achiral enolate such as 2, using the oxazoline (S)-3 as the source of chirality. Copyright 1999 Wiley-Liss, Inc.
RESUMO
In clinical trials to compare contraceptives, women are usually asked to record whether or not each day is a bleeding day over the duration of the trial. In this paper we describe how parametric models, which include terms corresponding to covariates recorded for each woman, can be used to analyse data on the occurrence of certain adverse events identified from the diary record. Linear logistic models are used to analyse the probability of prolonged bleeding or amenorrhoea, and log-linear models are used to analyse the lengths of bleeding episodes. In both cases variation between women is allowed for by including a random effect in the model. The application of our methods is illustrated using a data base made available by the World Health Organization.
